Litigation Details for Celgene Corporation v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2020)
✉ Email this page to a colleague
Celgene Corporation v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2020)
Docket | ⤷ Try a Trial | Date Filed | 2020-11-05 |
Court | Court of Appeals for the Federal Circuit | Date Terminated | 2021-11-05 |
Cause | Assigned To | ||
Jury Demand | Referred To | ||
Patents | 10,555,939; 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Celgene Corporation v. Mylan Pharmaceuticals Inc.
Details for Celgene Corporation v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2020)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2021-01-19 | 12 | ), Appx174-192; and 10,555,939 (the “᾿5,939 patent”). 5 … and 10,555,939 (“᾿5,939 patent”). This Court consolidated Celgene’s suits pertaining to the ’467 and…States Patents Nos. 8,198,262 (“’262 patent”); 8,673,939 (“’939 patent”); 8,735,428 (“’428 patent”); and…467 patent”); 10,093,647 (“’647 patent”); 10,093,648 (“’648 patent”); 10,093,649 (“’649 patent”); and… United States Patent Nos. 8,198,262 (the “’262 patent”); 8,673,939 (the “’939 patent”); 8,735,428 (the | External link to document | |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |